Standard

Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes. / Kuznetsova, Maria; Lopatnikova, Julia; Shevchenko, Julia и др.

в: Frontiers in Immunology, Том 10, № MAY, 1017, 09.05.2019, стр. 1017.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Kuznetsova, M, Lopatnikova, J, Shevchenko, J, Silkov, A, Maksyutov, A & Sennikov, S 2019, 'Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes', Frontiers in Immunology, Том. 10, № MAY, 1017, стр. 1017. https://doi.org/10.3389/fimmu.2019.01017

APA

Kuznetsova, M., Lopatnikova, J., Shevchenko, J., Silkov, A., Maksyutov, A., & Sennikov, S. (2019). Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes. Frontiers in Immunology, 10(MAY), 1017. [1017]. https://doi.org/10.3389/fimmu.2019.01017

Vancouver

Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A, Sennikov S. Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes. Frontiers in Immunology. 2019 май 9;10(MAY):1017. 1017. doi: 10.3389/fimmu.2019.01017

Author

Kuznetsova, Maria ; Lopatnikova, Julia ; Shevchenko, Julia и др. / Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes. в: Frontiers in Immunology. 2019 ; Том 10, № MAY. стр. 1017.

BibTeX

@article{ba7f04ab080b4b71946910dca6dec3cd,
title = "Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes",
abstract = "Minimal residual disease remaining after resection of primary tumors can lead to tumor recurrence and metastasis, increasing mortality and morbidity rates among cancer patients. Thus, there is a need for new technologies for recognition and elimination of single cancer cells remaining in a patient's body after radiation therapy, chemotherapy, or surgical resection. Effector CD8+ T cells, also commonly known as cytotoxic T lymphocytes (CTLs), play a key role in antitumor cellular immunity and, when properly activated, are able to effectively destroy tumor cells. The aims of this study were to obtain CD8+ CTLs specific for the HER2/neu epitopes E75 and E88 and to assess the cytotoxic activity and composition of these cells in terms of the distribution of memory T-cell subsets. We obtained HER2-specific CD8+ T cells and assessed T cell subset distribution among them including naive T cells (TN), central memory T cells (TCM), effector memory T cells (TEM), stem cell-like memory T cells (TSCM) and terminally-differentiated T cells (TEMRA) via eight-color flow cytometry. HER2-specific CTLs were largely (~40-50%) represented by TSCM cells, a population capable of mounting pronounced antitumor immune responses due to a combination of effector function and self-maintenance. In comparison with activated peripheral blood mononuclear cells (PBMCs) and bulk CD8+ T cells, HER2-specific CTLs exhibited greater cytotoxicity against the HER2-expressing human breast adenocarcinoma cell line MCF-7 and produced higher levels of IFN-γ in response to tumor cells. We also showed the presence of HER2-specific CTLs in healthy individuals and increase in them in HER2-positive breast cancer patients. Collectively, our results suggest that HER2-specific CD8+ T cells isolated using this approach could be used for adoptive T-cell transfer to eliminate tumor cells and prevent metastasis and relapse in patients with HER2-overexpressing cancers.",
keywords = "CD8+ T cells, cytotoxicity, HER2/neu, memory T cell subsets, stem cell-like memory T cells, Memory T cell subsets, Cytotoxicity, Stem cell-like memory T cells, IMMUNE-RESPONSE, DENDRITIC CELLS, CANCER, BREAST, IMMUNOTHERAPY, BIOLOGY, GROWTH, CD8(+) T cells, DIFFERENTIATION, EXPRESSION, LYMPHOCYTES",
author = "Maria Kuznetsova and Julia Lopatnikova and Julia Shevchenko and Alexander Silkov and Amir Maksyutov and Sergey Sennikov",
year = "2019",
month = may,
day = "9",
doi = "10.3389/fimmu.2019.01017",
language = "English",
volume = "10",
pages = "1017",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "MAY",

}

RIS

TY - JOUR

T1 - Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes

AU - Kuznetsova, Maria

AU - Lopatnikova, Julia

AU - Shevchenko, Julia

AU - Silkov, Alexander

AU - Maksyutov, Amir

AU - Sennikov, Sergey

PY - 2019/5/9

Y1 - 2019/5/9

N2 - Minimal residual disease remaining after resection of primary tumors can lead to tumor recurrence and metastasis, increasing mortality and morbidity rates among cancer patients. Thus, there is a need for new technologies for recognition and elimination of single cancer cells remaining in a patient's body after radiation therapy, chemotherapy, or surgical resection. Effector CD8+ T cells, also commonly known as cytotoxic T lymphocytes (CTLs), play a key role in antitumor cellular immunity and, when properly activated, are able to effectively destroy tumor cells. The aims of this study were to obtain CD8+ CTLs specific for the HER2/neu epitopes E75 and E88 and to assess the cytotoxic activity and composition of these cells in terms of the distribution of memory T-cell subsets. We obtained HER2-specific CD8+ T cells and assessed T cell subset distribution among them including naive T cells (TN), central memory T cells (TCM), effector memory T cells (TEM), stem cell-like memory T cells (TSCM) and terminally-differentiated T cells (TEMRA) via eight-color flow cytometry. HER2-specific CTLs were largely (~40-50%) represented by TSCM cells, a population capable of mounting pronounced antitumor immune responses due to a combination of effector function and self-maintenance. In comparison with activated peripheral blood mononuclear cells (PBMCs) and bulk CD8+ T cells, HER2-specific CTLs exhibited greater cytotoxicity against the HER2-expressing human breast adenocarcinoma cell line MCF-7 and produced higher levels of IFN-γ in response to tumor cells. We also showed the presence of HER2-specific CTLs in healthy individuals and increase in them in HER2-positive breast cancer patients. Collectively, our results suggest that HER2-specific CD8+ T cells isolated using this approach could be used for adoptive T-cell transfer to eliminate tumor cells and prevent metastasis and relapse in patients with HER2-overexpressing cancers.

AB - Minimal residual disease remaining after resection of primary tumors can lead to tumor recurrence and metastasis, increasing mortality and morbidity rates among cancer patients. Thus, there is a need for new technologies for recognition and elimination of single cancer cells remaining in a patient's body after radiation therapy, chemotherapy, or surgical resection. Effector CD8+ T cells, also commonly known as cytotoxic T lymphocytes (CTLs), play a key role in antitumor cellular immunity and, when properly activated, are able to effectively destroy tumor cells. The aims of this study were to obtain CD8+ CTLs specific for the HER2/neu epitopes E75 and E88 and to assess the cytotoxic activity and composition of these cells in terms of the distribution of memory T-cell subsets. We obtained HER2-specific CD8+ T cells and assessed T cell subset distribution among them including naive T cells (TN), central memory T cells (TCM), effector memory T cells (TEM), stem cell-like memory T cells (TSCM) and terminally-differentiated T cells (TEMRA) via eight-color flow cytometry. HER2-specific CTLs were largely (~40-50%) represented by TSCM cells, a population capable of mounting pronounced antitumor immune responses due to a combination of effector function and self-maintenance. In comparison with activated peripheral blood mononuclear cells (PBMCs) and bulk CD8+ T cells, HER2-specific CTLs exhibited greater cytotoxicity against the HER2-expressing human breast adenocarcinoma cell line MCF-7 and produced higher levels of IFN-γ in response to tumor cells. We also showed the presence of HER2-specific CTLs in healthy individuals and increase in them in HER2-positive breast cancer patients. Collectively, our results suggest that HER2-specific CD8+ T cells isolated using this approach could be used for adoptive T-cell transfer to eliminate tumor cells and prevent metastasis and relapse in patients with HER2-overexpressing cancers.

KW - CD8+ T cells

KW - cytotoxicity

KW - HER2/neu

KW - memory T cell subsets

KW - stem cell-like memory T cells

KW - Memory T cell subsets

KW - Cytotoxicity

KW - Stem cell-like memory T cells

KW - IMMUNE-RESPONSE

KW - DENDRITIC CELLS

KW - CANCER

KW - BREAST

KW - IMMUNOTHERAPY

KW - BIOLOGY

KW - GROWTH

KW - CD8(+) T cells

KW - DIFFERENTIATION

KW - EXPRESSION

KW - LYMPHOCYTES

UR - http://www.scopus.com/inward/record.url?scp=85067296953&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.01017

DO - 10.3389/fimmu.2019.01017

M3 - Article

C2 - 31143180

AN - SCOPUS:85067296953

VL - 10

SP - 1017

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - MAY

M1 - 1017

ER -

ID: 20591660